
The arrival of CAR-T cancer treatments and the expected coming age of cell therapies are opening new frontiers for what medicines look like: Cells are taken from patients, then tweaked or supercharged in a lab, and finally given back to patients.
But the emergence of those treatments has put a pinch on the places that collect those cells from patients. The crunch is only expected to grow as more CAR-T candidates and other cell therapies enter clinical trials and win approval.
These facilities, called apheresis centers, have already seen a spike in the number of patients coming through their doors with the first two CAR-T products on the market, in some cases forcing cancer patients to have to wait several days for a slot. Adding to the burden, center directors say, is that each company with a product or experimental therapy insists on performing its own audit to ensure its collection protocols are followed.
What is your monthly fee?
Do you accept credit cards?
GMW
Will this work with spinal cord injuries?